Replies to post #2522 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA FY3Q23* financials—6/30/23_cash=$393M:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-36

FY3Q23 royalty revenue was $18.9M.†

FY3Q23 R&D expenses were $43.0M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $165-175M.

FY3Q23 SG&A expenses were $12.6M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $50-55M.

†ENTA’s partial sale of Mavyret royalties took effect on 7/1/23, so it did not affect the FY3Q23 income statement.

*ENTA’s fiscal years end on September 30.